Abstract
To evaluate the predictive value of growth patterns in patients undergoing sorafenib treatment for metastatic clear cell renal cell carcinomas (CCRCCs). Forty-eight patients were analyzed, each of whom underwent nephrectomy and received sorafenib treatment for metastatic CCRCC. Progression-free survival (PFS) was predicted using pathologic parameters, including pathologic stage, Fuhrman nuclear grade (FNG), the presence of a sarcomatoid component, lymphovascular invasion, tumor necrosis, and growth pattern. Three (6%) patients showed partial response, 20 (42%) patients showed stable disease, and 25 (52%) patients showed progressive disease. Univariate analyses demonstrated that FNG, the presence of a sarcomatoid component, tumor necrosis, and growth pattern were significantly associated with PFS. In the multivariate analysis, growth pattern was the only parameter that was significantly and independently predictive of PFS. As a novel histologic prognostic parameter, growth pattern may be useful for predicting response to sorafenib treatment.
References
Mar 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A ZismanA S Belldegrun
Jul 4, 2001·The Journal of Urology·M W KattanP Russo
Apr 30, 2003·The American Journal of Surgical Pathology·John C ChevilleMichael L Blute
Jan 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerMadhu Mazumdar
Dec 14, 2004·The Journal of Urology·Maximiliano SorbelliniPaul Russo
Feb 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tarek M MekhailRonald Bukowski
Mar 7, 2006·The Journal of Urology·Vincenzo FicarraWalter Artibani
Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
Jan 12, 2007·The New England Journal of Medicine·Bernard EscudierUNKNOWN TARGET Study Group
Jan 16, 2007·The Journal of Urology·R Houston ThompsonIgor Frank
Jan 27, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Keith T Flaherty
May 12, 2007·European Urology·Paul C M S Verhagen
Jun 9, 2007·BJU International·Marcos F Dall'OglioMiguel Srougi
Jun 20, 2007·Cancer·Toni K ChoueiriRonald M Bukowski
Oct 24, 2007·Japanese Journal of Clinical Oncology·Hideyuki AkazaSeiji Naito
Oct 15, 2008·Molecular Cancer Therapeutics·Scott M WilhelmMark Lynch
Dec 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ali Reza GolshayanBrian I Rini
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Apr 3, 2009·BJU International·Sameer A SiddiquiMichael L Blute
Oct 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel Y C HengToni K Choueiri
Mar 2, 2011·Pathology International·Toshinori NishikimiMomokazu Gotoh
Nov 13, 2012·Urologic Oncology·Toni K ChoueiriSabina Signoretti
Apr 20, 2013·The Lancet Oncology·Robert J MotzerBrian I Rini
Sep 11, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerThomas E Hutson
Sep 21, 2013·American Journal of Clinical Pathology·Akitoshi FukatsuMomokazu Gotoh
Nov 28, 2013·Histopathology·Toyonori TsuzukiMomokazu Gotoh
Feb 22, 2014·The Lancet Oncology·Robert J MotzerBernard Escudier